Preprint Review Version 1 This version not peer reviewed

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Version 1 : Received: 10 September 2017 / Approved: 11 September 2017 / Online: 11 September 2017 (08:22:24 CEST)
Version 2 : Received: 6 October 2017 / Approved: 6 October 2017 / Online: 6 October 2017 (16:15:42 CEST)

How to cite: Ma, J.; Zhou, Q.; Li, H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy. Preprints 2017, 2017090040 (doi: 10.20944/preprints201709.0040.v1). Ma, J.; Zhou, Q.; Li, H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy. Preprints 2017, 2017090040 (doi: 10.20944/preprints201709.0040.v1).

Abstract

Gut microbiota play critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, and insulin resistance, which highlighted the potential of gut microbiota-targeted therapies on these diseases. There are various ways that can manipulate gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines. In this review, we first described the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies in NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiota-targeted therapies in the future.

Subject Areas

gut microbiota; obesity; insulin resistance; NAFLD; probiotic; prebiotic; symbiotic

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.